RGDXQ (Response Genetics) Effective Interest Rate on Debt %: 0.00% (As of Dec. 2015)


What is Response Genetics Effective Interest Rate on Debt %?

Response Genetics RGDXQ -98.00% Effective Interest Rate on Debt % is 0.00% as of Dec. 2015.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Response Genetics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2015 was $0.00 Mil. Response Genetics's average total debt for the quarter that ended in Dec. 2015 was $8.66 Mil. Therefore, Response Genetics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2015 was 0.00%.

Response Genetics  (OTCPK:RGDXQ) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Response Genetics Effective Interest Rate on Debt % Related Terms

Response Genetics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Response Genetics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Effective Interest Rate on Debt % Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.51 6.53 188.33 11.52 5.18

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.26 18.25 8.06 16.89 0.00

RGDXQ vs PSID, GBSN, ETAH: Effective Interest Rate on Debt % Comparison

For the Diagnostics & Research subindustry, Response Genetics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics Effective Interest Rate on Debt % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Response Genetics's Effective Interest Rate on Debt % falls into.


Response Genetics Effective Interest Rate on Debt % Calculation

Response Genetics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2015 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2014 )+Total Debt  (A: Dec. 2015 ))/ count )
=-1  *  -0.344/( (6.919+6.373)/ 2 )
=-1  *  -0.344/6.646
=5.18 %

where

Total Debt  (A: Dec. 2014 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=6.86 + 0.059
=6.919

Total Debt  (A: Dec. 2015 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.918 + 1.455
=6.373

Response Genetics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2015 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Mar. 2015 )+Total Debt  (Q: Dec. 2015 ))/ count )
=-1  *  0/( (10.943+6.373)/ 2 )
=-1  *  0/8.658
=0.00 %

where

Total Debt  (Q: Mar. 2015 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=10.838 + 0.105
=10.943

Total Debt  (Q: Dec. 2015 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.918 + 1.455
=6.373

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2015) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 0.00% mean?
Response Genetics (RGDXQ) has a Effective Interest Rate on Debt % of 0.00% as of Dec. 2015. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Response Genetics and its competitors.
Is Response Genetics' Effective Interest Rate on Debt % too high?
Response Genetics' current Effective Interest Rate on Debt % is 0.00%.
How does Response Genetics' Effective Interest Rate on Debt % compare to PSID and GBSN?
Response Genetics' Effective Interest Rate on Debt % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Medical Diagnostics & Research company?
A good Effective Interest Rate on Debt % depends on the Medical Diagnostics & Research industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Response Genetics and its competitors. Response Genetics's current Effective Interest Rate on Debt % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Effective Interest Rate on Debt % of 0.00%. The current Effective Interest Rate on Debt % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Effective Interest Rate on Debt % is 0.00% as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.